



US005877183A

United States Patent [19]
Cincotta

[11] **Patent Number:** **5,877,183**
[45] **Date of Patent:** **Mar. 2, 1999**

[54] **TREATMENT OF LIPID AND GLUCOSE METABOLISM DISORDERS WITH DOPAMINE AND SEROTONIN AGONISTS**

4,971,969 11/1990 Carlier et al. .
5,344,832 9/1994 Cincotta et al. .
5,468,755 11/1995 Cincotta et al. .
5,585,347 12/1996 Meier et al. 514/12

[75] Inventor: **Anthony H. Cincotta**, Charlestown, Mass.

OTHER PUBLICATIONS

[73] Assignee: **Ergo Research Corporation**, Wakefield, R.I.

International Preliminary Examination Report dated Apr. 1, 1998 received in the corresponding PCT application.

[21] Appl. No.: **864,885**

Primary Examiner—James H. Reamer
Attorney, Agent, or Firm—Darby & Darby

[22] Filed: **Jun. 6, 1997**

Related U.S. Application Data

[57] **ABSTRACT**

- [60] Provisional application No. 60/019,209 Jun. 6, 1996.
- [51] **Int. Cl.**⁶ **A61K 31/44**
- [52] **U.S. Cl.** **514/288**; 514/213; 514/339; 514/250; 514/866; 514/909
- [58] **Field of Search** 514/288, 213, 514/337, 250, 866, 909

Provided are methods for the regulation and modification of lipid and glucose metabolism by administering to a subject a dopamine D1 agonist, optionally in combination with a dopamine D2 agonist, an alpha-1 adrenergic antagonist, an alpha-2 adrenergic agonist, or a serotonergic inhibitor, or optionally in combination with a dopamine D2 agonist coadministered with at least one of alpha-1 adrenergic antagonist, an alpha-2 adrenergic agonist, or a serotonergic inhibitor, and further administering the subject a serotonin 5HT_{1b} agonist.

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,783,469 11/1988 Meier et al. .

21 Claims, 7 Drawing Sheets